Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea

CompletedOBSERVATIONAL
Enrollment

645

Participants

Timeline

Start Date

May 21, 2012

Primary Completion Date

December 15, 2015

Study Completion Date

December 15, 2015

Conditions
Acellular PertussisDiphtheriaTetanusPoliomyelitisDiphtheria-Tetanus-acellular Pertussis Vaccines
Interventions
OTHER

Infanrix-IPV data collection

Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.

Trial Locations (1)

130-702

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01568060 - Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea | Biotech Hunter | Biotech Hunter